17.3-Month Median Survival Reported for Immuneering's Pancreatic Cancer Drug
IMRX has more than doubled off its 52-week low of $1.4.
Summary
Immuneering reported a significant 17.3-month median overall survival for its drug atebimetinib in first-line metastatic pancreatic cancer patients from its Phase 2a trial. This strong clinical outcome, which also noted a consistent tolerability profile, provides crucial support for the company's recently launched registrational Phase 3 trial. The full data, including progression-free survival and safety, will be presented at the ASCO Annual Meeting on June 1st, followed by an investor conference call.
At the time of this announcement, IMRX was trading at $5.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $337.7M. The 52-week trading range was $1.40 to $10.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.